These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 29125016)

  • 1. Open for business: a comparative study of websites selling autologous stem cells in Australia and Japan.
    Munsie M; Lysaght T; Hendl T; Tan HL; Kerridge I; Stewart C
    Regen Med; 2017 Oct; 12(7):777-790. PubMed ID: 29125016
    [No Abstract]   [Full Text] [Related]  

  • 2. Online marketing practices of regenerative medicine clinics in US-Mexico border region: a web surveillance study.
    Chavez J; Shah NA; Ruoss S; Cuomo RE; Ward SR; Mackey TK
    Stem Cell Res Ther; 2021 Mar; 12(1):189. PubMed ID: 33736697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From the margins to mainstream: How providers of autologous 'stem cell treatments' legitimise their practice in Australia.
    MacGregor C; Petersen A; Munsie M
    Health (London); 2021 Jan; 25(1):51-68. PubMed ID: 31081381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploiting science? A systematic analysis of complementary and alternative medicine clinic websites' marketing of stem cell therapies.
    Murdoch B; Zarzeczny A; Caulfield T
    BMJ Open; 2018 Feb; 8(2):e019414. PubMed ID: 29490963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct-to-consumer marketing of stem cell interventions by Canadian businesses.
    Turner L
    Regen Med; 2018 Sep; 13(6):643-658. PubMed ID: 30255734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the Quality of Website Information of Private-Practice Clinics Offering Cell Therapies in Japan.
    Kashihara H; Nakayama T; Hatta T; Takahashi N; Fujita M
    Interact J Med Res; 2016 May; 5(2):e15. PubMed ID: 27222494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing "Cell Therapy" Clinics Offering Treatments of Ocular Conditions using Direct-to-Consumer Marketing Websites in the United States.
    Nirwan RS; Albini TA; Sridhar J; Flynn HW; Kuriyan AE
    Ophthalmology; 2019 Oct; 126(10):1350-1355. PubMed ID: 30904542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reassessing direct-to-consumer portrayals of unproven stem cell therapies: is it getting better?
    Ogbogu U; Rachul C; Caulfield T
    Regen Med; 2013 May; 8(3):361-9. PubMed ID: 23627829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current status of clinics providing private practice cell therapy in Japan.
    Fujita M; Hatta T; Ozeki R; Akabayashi A
    Regen Med; 2016 Jan; 11(1):23-32. PubMed ID: 26376631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions.
    Turner L
    Perspect Biol Med; 2018; 61(1):7-24. PubMed ID: 29805145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Australian regulation of autologous human cell and tissue products: implications for commercial stem cell clinics.
    Ghinea N; Munsie M; Rudge C; Stewart C
    Regen Med; 2020 Feb; 15(2):1361-1369. PubMed ID: 32228372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The direct-to-consumer market for stem cell-based interventions in Australia: exploring the experiences of patients.
    Waldby C; Hendl T; Kerridge I; Lipworth W; Lysaght T; Munsie M; Stewart C
    Regen Med; 2020 Jan; 15(1):1238-1249. PubMed ID: 32009513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Untested, unproven, and unethical: the promotion and provision of autologous stem cell therapies in Australia.
    McLean AK; Stewart C; Kerridge I
    Stem Cell Res Ther; 2015 Feb; 6(1):33. PubMed ID: 25689404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A roundtable on responsible innovation with autologous stem cells in Australia, Japan and Singapore.
    Lysaght T; Munsie M; Castricum A; Hui JHP; Okada K; Sato Y; Sawa Y; Stewart C; Tan LK; Tan LHY; Sugii S
    Cytotherapy; 2018 Sep; 20(9):1103-1109. PubMed ID: 30131270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid change of a cohort of 570 unproven stem cell clinics in the USA over 3 years.
    Knoepfler PS
    Regen Med; 2019 Aug; 14(8):735-740. PubMed ID: 31456478
    [No Abstract]   [Full Text] [Related]  

  • 16. The Need for Beneficence and Prudence in Clinical Innovation with Autologous Stem Cells.
    Lipworth W; Stewart C; Kerridge I
    Perspect Biol Med; 2018; 61(1):90-105. PubMed ID: 29805150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Untested Stem Cell Treatments: An Analysis of Australia's Current Regulatory Regime.
    Cavasinni N; Foong P
    J Law Med; 2024 May; 31(1):105-121. PubMed ID: 38761392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The involvement of Canadian physicians in promoting and providing unproven and unapproved stem cell interventions.
    Ogbogu U; Du J; Koukio Y
    BMC Med Ethics; 2018 May; 19(1):32. PubMed ID: 29716594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fake news portrayals of stem cells and stem cell research.
    Marcon AR; Murdoch B; Caulfield T
    Regen Med; 2017 Oct; 12(7):765-775. PubMed ID: 29115183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can civil lawsuits stem the tide of direct-to-consumer marketing of unproven stem cell interventions.
    Horner C; Tenenbaum E; Sipp D; Master Z
    NPJ Regen Med; 2018; 3():5. PubMed ID: 29479481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.